- Agreement to explore areas of collaboration in the digitalisation of healthcare solutions
- Evoteq to assist in the development and implementation of projects that enhance performance of the healthcare sector in Sharjah
- Sharjah Health Authority to work with Evoteq to devise an e-transformation plan for services
Evoteq has signed a Memorandum of Understanding with the Sharjah Health Authority (SHA), to collaborate on projects that facilitate the digital transformation of the healthcare sector in Sharjah. The agreement, whereby the SHA will seek to utilise Evoteq’s expertise in exploring the feasibility of digitally transforming its services, is intended at reforming the healthcare sector in the emirate by boosting productivity, quality and accessibility.
The agreement was formalised through a signing ceremony which took place on the 27th of December, between H.E. Abdullah Ali Al Mehyan, Chairman of Sharjah Health Authority, and H.E. Khaled Al Huraimel, CEO of Evoteq.
A digital venture that has rapidly established itself as a frontrunner in the region, Evoteq provides its services to government bodies and corporate establishments; which seek to digitalise their services and operations.
“The synergies and shared goals between Evoteq and the SHA are self-evident,” said H.E. Abdullah Ali Al Mehyan, “Evoteq seeks to facilitate digital transformation in the region, while the SHA seeks to transform the regional healthcare service industry. Through this agreement, we can work together to examine as to how digitally transformative solutions can be used to streamline the SHA’s operations. Efficient and affordable healthcare is a crucial condition for the emirate of Sharjah and by applying the benefits of technology to our services, we believe we can provide a sustainable healthcare system to our community, that aligns with international standards.”
For Evoteq, H.E. Khaled Al Huraimel said, “Evoteq was established with a vision of developing world-class digital solutions to address the challenges faced by a wide variety of industries, and optimising the performance of existing platforms for the benefit of our economy. Through the signing of this MoU, we will assist in the development of digital platforms, which can enhance the performance of the valuable services provided by the SHA. This agreement will have a revolutionary impact, not only on the SHA, but also on the wider healthcare sector in the UAE by setting a model for how digitalisation can improve and transform the sector’s capabilities. This will, in turn, contribute to our wider ambition of improving the overall quality of life in the UAE.”
His Highness Sheikh Sultan Bin Mohammed Bin Sultan Al Qasimi, Crown Prince and Deputy Ruler of Sharjah, had recently issued a resolution to form the “Higher Committee for Digital Transformation”, which will implement policies for the digitalisation of public services. Chaired by Sheikh Fahim Bin Sultan Al Qasimi, Chairman of the Government Relations Department, the committee is working towards establishing e-services, in alignment with international standards.
Commenting on the agreement between Evoteq & SHA, Sheikh Fahim, said: “Initiatives like this are testament to the value that can be created when the public and private sectors work together towards a common goal. Smart healthcare is one of the six key pillars of our digital transformation strategy in Sharjah”.
Earlier this year, Evoteq was awarded the contract to digitalise the services of the Sharjah Municipality, which constitutes the GCC’s largest municipal digitalisation project. Additionally, Evoteq has signed a MoU with the Ajman Digital Government (ADG) to explore the feasibility of executing digital government strategies for the transformation of public services in Ajman. The size and scope of these projects serves to illustrate how Evoteq is transforming the digital landscape within the UAE. Apart from agreements such as the MoU with SHA, Evoteq has also developed its own digital application, Smart Track, an advanced track and trace system which will effectively tackle the issue of counterfeit drugs in the medical industry.